![](/images/graphics-bg.png)
The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients
Joint Authors
Alegre, Estibaliz
González, Alvaro
Macías, Mónica
Alkorta-Aranburu, Gorka
Patiño-García, Ana
Mateos, Beatriz
Andueza, Maria P.
Gúrpide, Alfonso
Lopez-Picazo, Jose M.
Gil-Bazo, Ignacio
Perez-Gracia, Jose L.
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-01-23
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Epidermal growth factor receptor (EGFR) mutational testing in advanced non-small-cell lung cancer (NSCLC) is usually performed in tumor tissue, although cfDNA (cell-free DNA) could be an alternative.
We evaluated EGFR mutations in cfDNA as a complementary tool in patients, who had already known EGFR mutations in tumor tissue and were treated with either EGFR-tyrosine kinase inhibitors (TKIs) or chemotherapy.
We obtained plasma samples from 21 advanced NSCLC patients with known EGFR tumor mutations, before and during therapy with EGFR-TKIs and/or chemotherapy.
cfDNA was isolated and EGFR mutations were analyzed with the multiple targeted cobas EGFR Mutation Test v2.
EGFR mutations were detected at baseline in cfDNA from 57% of patients.
The semiquantitative index (SQI) significantly decreased from the baseline (median=11, IQR=9.5-13) to the best response (median=0, IQR=0-0, p<0.01), followed by a significant increase at progression (median=11, IQR=11-15, p<0.01) in patients treated with either EGFR-TKIs or chemotherapy.
The SQI obtained with the cobas EGFR Mutation Test v2 did not correlate with the concentration in copies/mL determined by droplet digital PCR.
Resistance mutation p.T790M was observed at progression in patients with either type of treatment.
In conclusion, cfDNA multiple targeted EGFR mutation analysis is useful for treatment monitoring in tissue of EGFR-positive NSCLC patients independently of the drug received.
American Psychological Association (APA)
Macías, Mónica& Alegre, Estibaliz& Alkorta-Aranburu, Gorka& Patiño-García, Ana& Mateos, Beatriz& Andueza, Maria P.…[et al.]. 2019. The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients. Disease Markers،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1147811
Modern Language Association (MLA)
Macías, Mónica…[et al.]. The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients. Disease Markers No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1147811
American Medical Association (AMA)
Macías, Mónica& Alegre, Estibaliz& Alkorta-Aranburu, Gorka& Patiño-García, Ana& Mateos, Beatriz& Andueza, Maria P.…[et al.]. The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1147811
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1147811